Sandusky, OH, Oct. 21, 2021 (GLOBE NEWSWIRE) — PAO Group, Inc. (OTC Pink: PAOG) today announced the launch of its second CBD nutraceutical product, RehabRX CBD, in a line of coming CBD products under the PAOG CBD “RX” brand name.
RehabRX is a rich formulation with beneficial botanicals proven to support healthy skin. RehabRX is free from any preservatives, colors or flavorings. The CBD comes from hemp grown in the state of Colorado. It is Gluten-free and Non-GMO.
PAOG has shipped its first and second CBD nutraceutical products to its distribution partner, North American Cannabis Holdings, Inc. (OTC Pink: USMJ). Earlier this week, PAOG introduced
RelaxRX
, a sleep aid. The products will soon be for sale online at
www.USMJ.com
with additional brick and mortar retail availability to follow.
PAOG expects revenue to grow rapidly as the company expands its CBD “RX” branded line of products.
Last year, PAOG acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960). PAOG is developing both
pharmaceutical
and nutraceutical treatments based on this intellectual property.
Learn more about USMJ’s ecommerce site at
www.usmj.com
.
Learn more about PAOG at
www.paogroupinc.com
.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
(888) 979-2675
[email protected]
